Orion keeps buying its own stock. It's not because the stock is cheap.

Every Friday afternoon this month, a Finnish drugmaker called Orion has put out the same press release. "Orion Corporation: Acquisition of own shares during week 37, 2026." A company of roughly €11 billion of market capitalization, quietly buying its own shares at about €80, not far from all-time highs, week after week. If you were raised on American market reflexes, you would read that as a signal: management thinks the stock is cheap, it's returning cash, EPS gets a mechanical lift, tide goes in.

Orion's version of the trade is stranger than that, and the strangeness lives in the purpose line. The program's stated job is to acquire shares for the company's share-based incentive plans — not to cancel them, not to return capital, but to hand the shares to employees. That is a different financial machine from the buyback your neighbor means when he says "buybacks are bullish." It is compensation plumbing, not capital allocation.

There are basically two kinds of buyback, and they do opposite things to the share count. The first: a company buys its shares and cancels them (or retires them in treasury forever), shrinking the float, mechanically lifting earnings per share, and returning the cash-equivalent value to the shareholders who stay. This is the one people get excited about, because it is a real capital-action statement — the company is betting on itself.

The second is the anti-dilution cousin: a company buys shares in the market specifically so it can deliver them to executives and employees under incentive plans, instead of printing brand-new shares. No net dilution, no EPS benefit, no cash lands in your pocket — the cash buys shares destined for other people inside the company. Orion's is the second kind. It isn't retiring anything; the shares sit in treasury (Orion held 508,972 of its own Class B shares after week 37) until the plan transfers them to participants.

The size tells you how little this is a statement about value. Across the two weeks it has run, the program bought about 240,800 shares for just under €20 million. Set against an €11 billion market cap, that is roughly two-tenths of one percent of the company. The whole program is capped at 500,000 Class B shares and €45 million — an envelope sized to keep employee-compensation cost tiny, not to move a stock. A genuine capital-return program on a business this size would run multiples of that and would take shares out of circulation.

That is also why every release is so dutifully rigid about mechanics. The purchases are executed by an outside broker (Danske Bank), which makes its own timing decisions, under the EU's market-abuse-regulation safe harbor for buybacks, with its daily volume limits, price limits, blackout discipline, and mandatory weekly disclosure. In American markets, buybacks are a quieter, more discretionary affair; in Europe, a company buying its stock under a safe harbor has to report it on schedule, and the schedule is why this modest exercise produces a press release every single week. It is plumbing making noise.

Now, some of that noise is worth correctly reading for what it is not: a buyback for incentive plans tells you nothing about whether €80 is cheap. What it tells you is that Orion pays its people partly in stock and would rather source the shares in the market than dilute existing holders when it does. That is a mild positive for ongoing shareholders — a company quietly choosing not to dilute you — but it is a background courtesy, not a thesis.

The actual Orion story, for an investor deciding whether the company belongs on a watch list, is sitting a few features down the same newsfeed. Orion's growth is being driven by Nubeqa, a prostate-cancer drug partnered with Bayer; in the second quarter its operating profit jumped about 69% year over year, and on the very day the week-37 release landed, the company said the annual Nubeqa net sales it records have "the potential to exceed EUR 1 billion in the future" — this against 2026 guidance of roughly €2.0–2.1 billion of net sales and €650–750 million of operating profit. Nubeqa is the story. The buyback is a rounding error beside it.

If you want the Orion read, the interesting mechanical detail is the accounting timing quirk the company itself flags: each quarter's product deliveries to Bayer are fully deducted from the next quarter's royalty payments, so operating profit wobbles from quarter to quarter around a growing trend. That, and the fact that a growing royalty stream depends on a partner's forecasts, is the live risk — not the Friday buyback ticker. The weekly press release is a pebble dropped into the pond every Friday. The Nubeqa royalties are the rock.